Warning: count(): Parameter must be an array or an object that implements Countable in /homepages/9/d27096167/htdocs/hauttumorzentrum/wordpress/wp-content/plugins/user-specific-content/User-Specific-Content.php on line 373

Zentrum Dermatologische Onkologie Tübingen

CA209-066 (BMS)


Warning: count(): Parameter must be an array or an object that implements Countable in /homepages/9/d27096167/htdocs/hauttumorzentrum/wordpress/wp-content/plugins/user-specific-content/User-Specific-Content.php on line 373

Randomisierte, doppel-blinde Phase III Studie mit BMS-936558 (Nivolumab) gegenüber DTIC mit nicht-resektablen, nicht-vorbehandeltem metastasierten Melanom

Krankheitsstadium: Melanom, Stadium III (nicht-resezierbar)/IV

Weitere Information: http://clinicaltrials.gov/show/NCT01721772

 

A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Stage of disease: Melanoma, Stage III (unresectable)/IV

Further Information: http://clinicaltrials.gov/show/NCT01721772

Autor: Dr. med. Thomas Eigentler

thomas.eigentler@med.uni-tuebingen.de | Tel. ++49 7071 29 85748

Kommentare sind geschlossen.